Reduction of direct and indirect costs in patients with AS receiving etanercept: results from an open-label 36-week extension of the ASCEND study in four European countries
Open Access
- 29 December 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 51 (2) , 393-396
Abstract
Objective. To characterize the impact of etanercept (ETN) in AS on cost, work productivity and quality of life (QoL). Methods. A Phase 4, open-label, multi-centre (UK, Scandinavia) extension study in AS. Eligible subjects (n = 84) were treated for 36–52 weeks with ETN 50 mg s.c. once weekly. Analysis included direct costs (transformed out-patient and in-patient care elements), indirect costs (sick leave and lost working days), efficacy and QoL. Results. Annualized direct and indirect costs decreased (55.5%, P ≤ 0.008) during ETN treatment, as did out-patient and in-patient episodes (physiotherapist/physician visits, P = 0.012). Work productivity and QoL increased. Conclusion. ETN therapy significantly reduces direct and indirect health-care costs and increases work ability and QoL in AS. Trial Registration. EUDRACT, https://eudract.ema.europa.eu/, 2006-001061-42.Keywords
This publication has 10 references indexed in Scilit:
- Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: A randomized, double-blind trialArthritis & Rheumatism, 2011
- Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitisAnnals of the Rheumatic Diseases, 2010
- Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal costAnnals of the Rheumatic Diseases, 2010
- Tumour necrosis factor inhibitors in ankylosing spondylitisInternal Medicine Journal, 2008
- Impact of ankylosing spondylitis on work and family life: Comparisons with the US populationArthritis Care & Research, 2008
- The direct healthcare costs associated with ankylosing spondylitis patients attending a UK secondary care rheumatology unitRheumatology, 2008
- Influence of biologic therapy on return to work in people with work disability due to ankylosing spondylitisRheumatology, 2007
- A review of work-participation, cost-of-illness and cost-effectiveness studies in ankylosing spondylitisNature Clinical Practice Rheumatology, 2006
- Impact of anti-tumour necrosis factor α treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitisAnnals of the Rheumatic Diseases, 2004
- Ankylosing spondylitis: an overviewAnnals of the Rheumatic Diseases, 2002